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INTRODUCTION :
Teriparatide, a recombinant form of parathyroido hormone, were
well recognized as a useful option for the treatment of the osteo-
porosis (1-3). Intermittent injection of teriparatide activates os-
teoblasts and results in incresase in bone mineral density (1, 3).
It has been demonstrated to effectively reduce vertebral and non-
vertebral fractures, and back pain in postmenopausal osteoporotic
patients (3-6). Some side effects of teriparatide include headache,
nausea, dizziness, and limb pain were reported as “common” to
“very common” by the European Medicines Agency (3, 7, 8). Al-
though reports of decreased blood pressure after injection of teri-
paratide were present, there is no detailed case report about the
severe reduction in blood pressure of each injection and suggesting
drug interaction between hypotensive agents and teriparatide. This
potential drug interaction and its clinical consequences have not
been discussed.
Here we present a 80-year-old woman of transient asymptomatic
hypotension as acute-phase reactions with once-weekly subcuta-
neous injection of teriparatide for the treatment of osteoporosis
with hypertension disease. Systolic, diastolic blood pressure and
heart rate after injection were studied. To the best of our knowl-
edge, this is the first report about the severe reduction in blood
pressure of each injection of once-weekly teriparatide and suggest-
ing drug interaction with hypotensive agents.
CASE PRESENTATION :
A 80-year-old woman with hypertension disease had a chronic
low back pain due to spondylolisthesis at L4/5 and old lumbar com-
pression fractures at L2, L3, and L4 (Figure 1). She consulted our
clinic to relief of her low back pain. She was 54 kg and 144 cm ;
body mass index was 26.0 kg/m2. Bone metabolic markers, P1NP
and TRAcP-5b, and bone mineral density at spine and femoral neck
were evaluated before and after treatment (Table 1). She had not
been receiving anti -osteoporotic medical therapy, although the pa-
tient had hypertension disease treated with hypotensive agents,
valsartan (80 mg/day), hydrochlorothiazide (12.5 mg/day), atenolol
(25 mg/day), and amlodipine besilate (6.93 mg/day), once a day
in the morning. The physical examination was normal without neu-
rological signs, except for an apparent slight thoraco- lumbar kypho-
sis. All laboratory findings were within normal limits. She has no
history of autonomic dysfunction and transient hypotensive reaction.
Once-weekly subcutouneous injection of teriparatide (hPTH
(1-34), teriparatide acetate, TERIBONETM, 56.5 μg, Asahi Kasei
Pharma, Tokyo, Japan), injected at 14 O’clock, was applied to the
patient for 24 weeks. As a safety management, systolic, diastolic
blood pressure and heart rate were measured before, 30 min. after,
and 60 min. after every subcutaneous injection of teriparatide.
Blood pressure was measured using automatic devices (AC 05P,
SUZUKEN CO., LTD. Aichi, Japan.) in sitting position with the
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arms supported precisely at the right atrium level. The subjective
symptoms were also interviewed at every blood pressure meas-
urement.
Transient asymptomatic hypotension was observed each time of
subcutaneous injection of teriparatide. Slight nausea was seen as
subjective symptoms with the first and second injection after 30
min. Systolic blood pressure, diastolic blood pressure, and heart
rate were shown in Figure 2. Systolic blood pressure decreased
in both 30 min and 60 min after injection compared with before
injection. Systolic blood pressure was still low after 60 min, but
slightly recovered. Diastolic pressure decreased after 30 min in-
jection, but recovered in 60 min. There were no significant differ-
ence between before and 60 min after injection. Heart rate slightly
increased with passage of time. Statistically significant in heart rate
were observed among before, 30 min, 60 min after injection of
teriparatide. This slight tachycardia was intended to compensate
for the decrease in blood pressure. However, these increase were
small and considered to be less clinical significance. The changes
in bone metabolic markers and bone mineral density in this case
were also small and clinically not significant (Table 1). These re-
sults were consistent with previous report (9). At one-year follow-
up, low back pain decreased and no other side effect of the treat-
ment was observed.
DISCUSSION
According to the formally prescribing information (10), the maxi-
mum decrease of systolic and diastolic blood pressure during their
clinical pharmacological test was 4.6 mmHg and 8.8 mmHg, respec-
tively. In this case, the maximum decrease of systolic and diastolic
blood pressure was 66 mmHg and 32 mmHg, respectively. These
Figure 1. Anteroposterior (A) and lateral (B) radiographs. Spondylolisthesis (natural fusion) at L4/5 and old lumbar compression fractures at
L2, L3, and L4 were observed.
Figure 2. Line graphs demonstrating systolic blood pressure (A), dia-
stolic blood pressure (B), and heart rate (C). Statistical analyses were
performed using SPSS v. 21.0. Values of p0.05 were considered sig-
nificantly different. The effects of teriparatide were analyzed using a Fried-
man test. The homogeneity of variances was analyzed using the Shapiro -
Wilk normality test. *, statistically significant difference.
Table 1. The change inbonemineral density andbonemetabolicmarkers.
Before treatment After treatment
BMD at spine
(T-score) 0.982 g/cm
2 (0.97) 1.002 g/cm2 (0.99)
BMD at femoral
neck (T-score) 0.487 g/cm
2 (0.62) 0.485 g/cm2 (0.62)
P1NP 46.6 μg/l 56.3 μg/l
TRAcP-5b 448 mU/dl 402 mU/dl
Bone metabolic markers were evaluated one week before the first injec-
tion of teriparatide and after the last injection of teriparatide. Bone min-
eral density (BMD).
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strikingly decreases were observed after 30 min injection compared
with the maximum decrease in blood pressure prescribed in the
formal information (8). This is the first report describing such a
severe transient hypotension after once-weekly injection of teri-
paratide.
The mechanism of hypotension after injection of teriparatide was
generally believed due to the vasodilating action through the vas-
cular smooth muscle relaxant activity, accompanied by pulse in-
crease (11, 12). Hypotension has multiple possible causes, and
hypotensive agents such as Ca2 antagonist reduce vascular smooth
muscle tone with increase of vessel diameter and decrease of the
blood pressure (13). Transient hypotension reaction in this case
may have reflected the response to multiple hypotensive agents
rather than the consequence of a drug interaction between hy-
potensive agents and teriparatide (14). However, hypotensive reac-
tion had never been observed without injection of teriparatide dur-
ing follow up period. This case indicates the necessity considering
the drug interaction between hypotensive agents and teriparatide,
although there is no such description in the formal information and
no report suggesting the drug interaction between hypotensive
agents and teriparatide.
This case also showed that most hypotensive side effects did not
cause the subjective symptom. Although systolic and diastolic blood
pressure decreased after each injection of teriparatide, transient
hypotension was usually asymptomatic except for the first 2 injec-
tions. The decrease of systolic blood pressure after first injection
and second injection was 17 mmHg and 28 mmHg, respectively.
As far in this patient, these decreases were the average changes
for her. Given the results from this case, there is a possibility that
asymptomatic decrease in blood pressure might occur in acute
phase after injection of teriparatide.
CONCLUSION
Here we show a severe transient asymptomatic hypotension with
once-weekly subcutaneous injection of teriparatide for the treatment
of osteoporosis with hypertension disease as acute-phase reactions.
This is a first report showing transient severe hypotension after
once-weekly injection of teriparatide in acute phase, and suggesting
the drug interaction between hypotensive agents and teriparatide.
This case indicates careful attention, at least 1 hr, was recommended
with injections of teriparatide in the treatment for osoteoproteic
patient with hypertension decreases. There is a possibility that tran-
sient hypotension might occur without symptoms in acute phase
after injection of teriparatide.
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